Lampropoulou-Adamidou K, Tournis S, Triantafyllopoulos I K
Laboratory for Research of the Musculoskeletal System 'Th. Garofalidis', Medical School, University of Athens, General Hospital of Athens KAT, Greece.
J Musculoskelet Neuronal Interact. 2016 Mar;16(1):75-8.
There are numerous studies presenting the beneficial effect of bisphosphonates (BPs) on bone disease of patients suffering from beta-thalassemia major (TM). Although BPs have been widely used, adverse events have been described including atypical femoral fractures (AFF). In the present case, a male adult patient suffering from TM sustained an AFF fulfilling all major and two minor criteria. Before AFF, the patient had been treated with zoledronic acid for three years and remained another one year without osteoporosis therapy. To our knowledge, this is the first reported case of AFF in a patient suffering from TM, probably due to the small sample size of patients with thalassemia. The purpose of the present case is to increase the awareness amongst haematologists, who mainly deal with TM patients, of the adverse events of BP use.
有大量研究表明双膦酸盐（BPs）对重型β地中海贫血（TM）患者的骨病具有有益作用。尽管BPs已被广泛使用，但已报道了包括非典型股骨骨折（AFF）在内的不良事件。在本病例中，一名成年男性TM患者发生了符合所有主要标准和两项次要标准的AFF。在发生AFF之前，该患者已接受唑来膦酸治疗三年，且在未进行骨质疏松治疗的情况下又持续了一年。据我们所知，这是首例报道的TM患者发生AFF的病例，可能是由于地中海贫血患者样本量较小。本病例的目的是提高主要诊治TM患者的血液科医生对使用BPs不良事件的认识。
